Regeneron Pharmaceuticals, Inc. (4REGN)
Summary
4REGN Chart
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic moves in obesity drugs aim for future growth.
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.
Regeneron Pharmaceuticals, Inc. Dividends
| REGN In 1 day Announced | Quarterly | $0.88 Per Share |
Regeneron Pharmaceuticals, Inc. Earnings
| 30 Oct 2025 (In 2 months) Date | | 9.65 Cons. EPS | - EPS |
| 30 Oct 2025 (In 2 months) Date | | 9.52 Cons. EPS | - EPS |
| 29 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 1 Aug 2025 Date | | 8.03 Cons. EPS | - EPS |
| 30 Jul 2025 Date | | 8.53 Cons. EPS | 12.89 EPS |
| REGN In 1 day Announced | Quarterly | $0.88 Per Share |
| 30 Oct 2025 (In 2 months) Date | | 9.65 Cons. EPS | - EPS |
| 30 Oct 2025 (In 2 months) Date | | 9.52 Cons. EPS | - EPS |
| 29 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 1 Aug 2025 Date | | 8.03 Cons. EPS | - EPS |
| 30 Jul 2025 Date | | 8.53 Cons. EPS | 12.89 EPS |
Regeneron Pharmaceuticals, Inc. (4REGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Regeneron Pharmaceuticals, Inc. ever had a stock split?
Regeneron Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Leonard S. Schleifer CEO | XMIL Exchange | US75886F1075 ISIN |
| US Country | 15,158 Employees | 18 Aug 2025 Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Products and Services
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
- EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
- Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
- Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
- REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
- Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
- Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
- ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
- ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.
Contact Information
